The hit that came out of our genome-wide CRISPR/Cas9 screen is now published. SYCP3, a meiosis-specific gene not normally expressed in somatic tissue, is frequently upregulated in prostate tumours from patients at advanced stages. We show that it enhances metastasis and modulates the DNA damage response pathway.
Led by María Rodrigo-Faus, with Inés del Monte-García, Marina Hermosilla-Trespaderne and Alicia Gordo-Vega from the lab, and in collaboration with the groups of Almudena Porras, Daniel Sanchez-Parcerisa, Paloma Bragado and Hakon Hakonarson.
Rodrigo-Faus M, del Monte-Garcia I, Hermosilla-Trespaderne M, et al. SYCP3 enhances prostate cancer metastasis and modulates the DNA damage response pathway. Scientific Reports. 2026 Aug 3. doi: 10.1038/s41598-026-64241-0.
